MedTrace Logo

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00606684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2016-12-16

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GW642444 6.25

GW642444 6.25

DRUG

GW642444 3mcg

once daily

DRUG

GW642444 12.5mcg

GW642444 12.5mcg

DRUG

GW642444 25mcg

GW642444 25mcg

DRUG

GW642444 50mcg

GW642444 50mcg

OTHER

placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Argentina
  • Canada
  • Chile
  • Denmark
  • Estonia
  • Germany
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Russia
  • Slovakia
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606684 on ClinicalTrials.gov